- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Jones Trading stuft RenovoRx mit "Buy" ein - Kurspotenzial von über 700 % | 1 | Investing.com Deutsch | ||
| Fr | Jones Trading initiates coverage on RenovoRx stock with Buy rating | 2 | Investing.com | ||
| Mi | RenovoRx, Inc.: RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific Meeting | 2 | GlobeNewswire (USA) | ||
| 20.01. | RenovoRx, Inc.: RenovoRx Expands RenovoCath Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer Center | 1 | GlobeNewswire (USA) | ||
| 14.01. | RenovoRx, Inc.: RenovoRx to Participate in AlphaNorth Capital Event, January 16-18, 2026 | 5 | GlobeNewswire (USA) | ||
| 08.01. | RenovoRx, Inc.: RenovoRx To Announce Promising New Clinical Data Using its TAMP Therapy Platform in an Abstract to be Presented at ASCO GI 2026 | 1 | GlobeNewswire (USA) | ||
| 02.01. | RenovoRx, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| RENOVORX Aktie jetzt für 0€ handeln | |||||
| 19.11.25 | RenovoRx, Inc.: RenovoRx CEO Shaun Bagai to Present at the Alliance Global Partners Emerging AgBiotech/Bio-Solutions Virtual Showcase on November 20th | 1 | GlobeNewswire (USA) | ||
| 13.11.25 | RenovoRx, Inc.: RenovoRx Reports Third Quarter 2025 Financial Results, Including Approximately $900,000 in Year-to-Date Revenue, and Provides Business Update | 197 | GlobeNewswire (Europe) | September 30, 2025 Cash and Cash Equivalents at $10 million Revenue Expected to Grow in 2026 and Continue to Offset Cash Burn Management to Host Conference Call Today at 4:30 p.m. ET MOUNTAIN VIEW... ► Artikel lesen | |
| 13.11.25 | RenovoRx, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 13.11.25 | RenovoRx, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 06.11.25 | UCLA oncology surgeon joins RenovoRx's scientific advisory board | 1 | Investing.com | ||
| 06.11.25 | RenovoRx, Inc.: RenovoRx Strengthens Scientific Advisory Board (SAB) with Pancreatic Cancer Expert Timothy Donahue, MD | 1 | GlobeNewswire (USA) | ||
| 04.11.25 | RenovoRx, Inc.: RenovoRx CEO Shaun Bagai to Participate at the Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum on November 20th | 1 | GlobeNewswire (USA) | ||
| 09.10.25 | RenovoRx adds interventional oncology expert to scientific advisory board | 2 | Investing.com | ||
| 09.10.25 | RenovoRx, Inc.: RenovoRx Expands Scientific Advisory Board with Internationally Renowned Interventional Oncologist, Thierry de Baère, MD, PhD | 1 | GlobeNewswire (USA) | ||
| 26.09.25 | RenovoRx reports first patient procedure with RenovoCath | 1 | MassDevice | ||
| 25.09.25 | First registry-eligible patient procedure completed in RenovoRx's study | 1 | Investing.com | ||
| 25.09.25 | RenovoRx, Inc.: RenovoRx's PanTheR Post-Marketing Registry Study Progresses with First Clinical Procedure and Addition of Two Participating Clinical Sites | 1 | GlobeNewswire (USA) | ||
| 14.08.25 | RenovoRx: EPS übertrifft Schätzungen - Umsatz schlechter als erwartet | 15 | Investing.com Deutsch |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 95,80 | -0,21 % | BASF unter DRUCK! KAUFEMPFEHLUNGEN für BioNTech und WashTec Aktie! | Marktführerschaft, Effizienzsteigerung, Dividende und Aktienrückkauf - alles gute Gründe, um die Aktie von WashTec zu kaufen. Diese Einschätzung teilen auch die Analysten von MM Warburg. Ihre Gewinnschätzungen... ► Artikel lesen | |
| MODERNA | 36,760 | -1,17 % | Moderna, Inc.: Dr. David Berman to Join Moderna as Chief Development Officer | CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / January 30, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that David Berman, M.D., Ph.D. has been appointed as the Company's Chief Development Officer... ► Artikel lesen | |
| BIOGEN | 149,10 | +1,19 % | Biogen Says FDA Grants Breakthrough Therapy Designation For Litifilimab To Treat CLE | WESTON (dpa-AFX) - Biogen, Inc. (BIIB) announced Wednesday that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for litifilimab (BIIB059) for the treatment... ► Artikel lesen | |
| ILLUMINA | 122,04 | -0,08 % | Illumina, Inc.: Illumina completes acquisition of SomaLogic from Standard BioTools Inc. | Deeply expands leadership in proteomics and multiomicsCombined capabilities bring high scalability, flexibility, and affordability into protein analysis Combination leverages SomaScan with Illumina's... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 42,000 | -0,47 % | Citizens senkt Kursziel für CRISPR Therapeutics auf 80 US-Dollar, bleibt aber optimistisch | ||
| VIKING THERAPEUTICS | 24,780 | +1,02 % | Eli Lilly or Viking Therapeutics: Which Stock Is More Likely to be a Millionaire-Maker? | ||
| ATAIBECKLEY | 3,765 | -2,33 % | Psychodelika-Aktien: Sind Bioxyne, Compass Pathways und Atai "the next big thing"? | ||
| TWIST BIOSCIENCE | 34,380 | -0,87 % | Earnings Outlook For Twist Bioscience | ||
| BIOXCEL THERAPEUTICS | 1,294 | -3,29 % | BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI | NEW HAVEN, Conn., Jan. 07, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence ("AI") to develop transformative medicines... ► Artikel lesen | |
| BRIACELL THERAPEUTICS | 3,600 | -1,10 % | BriaCell Therapeutics Corp.: BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients | 9 of 25 BriaCell patients treated since 2022 remain alive >18-47 months post enrollment, markedly exceeding benchmarks reported for standard of care therapies in similar patient populationsNo Bria-IMT... ► Artikel lesen | |
| VISTAGEN THERAPEUTICS | 0,559 | +3,23 % | Vistagen Therapeutics, Inc. - 8-K, Current Report | ||
| QIAGEN | 44,620 | +0,64 % | QIAGEN: Wochengewinner im DAX - Analyse der KW 4 | ||
| PRAXIS PRECISION MEDICINES | 314,30 | -0,12 % | H.C. Wainwright raises Praxis Precision Medicines stock price target to $1,245 | ||
| NUVALENT | 102,89 | +0,45 % | Royalty Pharma plc: Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million | NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a pre-existing royalty interest in Nuvalent's neladalkib and zidesamtinib from an... ► Artikel lesen | |
| NURIX THERAPEUTICS | 16,520 | -6,03 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update | First patients dosed in DAYBreak registrational program for bexobrutideg in relapsed/refractory CLLPresented Phase 1 results at ASH 2025 that support bexobrutideg's potential best-in-class profile... ► Artikel lesen |
Das Unternehmen RENOVORX INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,040 Euro und damit +7,91 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RENOVORX INC finden Sie auf Wallstreet Online.